Overview A Study in Patients With Advanced or Metastatic Cancer Status: Completed Trial end date: 2012-07-01 Target enrollment: Participant gender: Summary Study JWAA is a multicenter, nonrandomized, open-label, dose-escalation Phase 1 study of oral LY2780301 in patients with advanced solid tumors. Phase: Phase 1 Details Lead Sponsor: Eli Lilly and Company